Folic Acid
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Folic Acid: From Vitamin Supplementation to Biotin Metabolic Disease
One-Sentence Summary
Folic acid (vitamin B9) is a well-established vitamin supplement, generally used to treat and prevent folate deficiency. The TxGNN model predicts a possible role in biotin metabolic disease, but this is currently supported only by indirect, mechanism-level literature and general micronutrient trials, with 13 clinical trials and 20 publications identified — none of which directly test folic acid in this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack (no licences or original-indication data recorded); folic acid is generally used for folate-deficiency states |
| Predicted New Indication | Biotin metabolic disease |
| TxGNN Prediction Score | 99.49% (rank 5125) |
| Evidence Level | L4 (mechanism/review-level only; no dedicated trials) |
| UK Market Status | Not marketed (per evidence pack) |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in this evidence pack (data gap DG002). Based on general pharmacological knowledge, folic acid is a water-soluble B-vitamin (vitamin B9) that acts as a cofactor in one-carbon metabolism, supporting DNA synthesis and methylation reactions; its efficacy in treating folate deficiency and preventing neural tube defects is well established.
Biotin metabolic disease (e.g. biotinidase deficiency and related biotin-responsive disorders) belongs to a broader group of “vitamin-responsive inborn errors of metabolism,” in which several B-vitamins — including folate, cobalamin (B12), and biotin — act as coenzymes for related metabolic pathways. This shared classification, rather than a direct pharmacological mechanism, is the most plausible basis for the TxGNN association.
The supporting literature (e.g. PMID 23622402, “Vitamin-responsive disorders: cobalamin, folate, biotin, vitamins B1 and E”) discusses folate and biotin together as cofactor-dependent conditions, but no publication or trial identified here directly evaluates folic acid as a treatment for biotin metabolic disease specifically. The prediction should therefore be regarded as mechanistically plausible in a general “vitamin cofactor” sense, rather than as evidence of a direct therapeutic effect.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT05687474 | N/A | Completed | 6824 | Universal newborn genomic screening panel covering 126 treatable early-onset genetic diseases, including biotin/vitamin-responsive metabolic disorders |
| NCT01173315 | Phase 2 | Completed | 75 | Vitamin and mineral supplementation for neuropathy/nephropathy in type 2 diabetes, not biotin metabolic disease specific |
| NCT04586348 | Phase 4 | Active, not recruiting | 794 | Prenatal iodine/vitamin supplementation and childhood neurodevelopment |
| NCT01643187 | Phase 2 | Unknown | 1000 | Fortified food vs. milk on nutritional/micronutrient status, including serum folic acid |
| NCT04312152 | N/A | Unknown | 200 | Multivitamin B/E and Q10 support therapy in autism spectrum disorder and Phelan-McDermid syndrome |
| NCT01474486 | N/A | Completed | 40 | Multi-micronutrient intervention in congestive heart failure |
| NCT03444155 | N/A | Completed | 30 | Natural vs. synthetic vitamin B complex bioavailability |
| NCT00572741 | N/A | Completed | 39 | Targeted nutritional/methylation support in autism |
| NCT03360435 | N/A | Completed | 99 | Transdermal vitamin absorption after bariatric surgery |
| NCT01558193 | N/A | Completed | 202 | Multivitamin/mineral and fatty acid supplementation on impulsivity and aggression |
None of the identified trials directly evaluate folic acid for biotin metabolic disease; all are general micronutrient/vitamin supplementation studies in unrelated populations.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23622402 | 2013 | Review | Handbook of Clinical Neurology | Discusses cobalamin, folate and biotin as coenzymes in vitamin-responsive inborn errors of metabolism |
| 30557456 | 2019 | Review | Movement Disorders | Reviews movement disorders in treatable inborn errors of metabolism, including vitamin-responsive conditions |
| 958746 | 1976 | Review | Pediatric Clinics of North America | Discusses megavitamin-responsive aminoacidopathies and B-vitamin coenzyme mechanisms |
| 779426 | 1976 | Review | Advances in Human Genetics | Reviews vitamin-responsive inherited metabolic disorders |
| 7027768 | 1981 | Review | Acta Vitaminologica et Enzymologica | Reviews vitamin roles in metabolic disease pathogenesis, including malabsorption and vitamin-dependent syndromes |
| 16343871 | 2006 | Review | Archives de Pédiatrie | Reviews neonatal epilepsy secondary to inborn errors of metabolism, including vitamin-responsive causes |
| 11031989 | 2000 | Review | Ryoikibetsu Shokogun Shirizu | Reviews vitamin dependency syndromes |
| 6396715 | 1984 | Review | Progress in Food & Nutrition Science | Discusses effects of B-vitamin (including biotin) deficiency on cell-mediated immunity |
| 14989256 | 2004 | Review | Archives of Biochemistry and Biophysics | Discusses DNA damage from folate/B12/biotin deficiency and rationale for micronutrient optimisation |
| 4279121 | 1974 | Review | Biomembranes | Reviews absorption mechanisms of water-soluble vitamins, including folate and biotin |
No RCTs or case reports specific to folic acid treatment of biotin metabolic disease were identified; all relevant literature is review/mechanism-level, discussing folate and biotin jointly within the broader vitamin-responsive metabolic disorder category.
UK Market Information
No marketing authorisation was identified for folic acid in this evidence pack (market status: Not marketed; 0 licences recorded). This should be independently verified against the MHRA products database and the NHS Dictionary of Medicines and Devices (dm+d), as folic acid products are commonly authorised and prescribed in the UK for other indications; the absence of a licence record here reflects a gap in the evidence pack rather than a confirmed regulatory status.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: TFDA-equivalent warning/contraindication data is flagged as a Blocking data gap (DG001) in this evidence pack and could not be incorporated into this assessment.
Conclusion and Next Steps
Decision: Hold
Rationale: The link between folic acid and biotin metabolic disease is currently supported only by general reviews grouping folate and biotin as related vitamin cofactors, with no dedicated trial or study evaluating this specific drug-disease pair. Combined with a blocking safety data gap (DG001) and no confirmed UK marketing authorisation on record, the evidence is insufficient to proceed further at this time.
To proceed, the following is needed:
- UK SmPC/BNF-sourced warnings, contraindications and interaction data (resolve DG001)
- Confirmed mechanism of action data from DrugBank or equivalent source (resolve DG002)
- Verification of actual UK licensing status via MHRA/dm+d
- Any dedicated preclinical or clinical study directly assessing folic acid in biotin-responsive or biotin metabolic disease, rather than general multivitamin supplementation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.